Trials / Completed
CompletedNCT04988282
Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 262 (actual)
- Sponsor
- Turkish Thoracic Society · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19 Interstitial Lung Disease. Method: Method: In this multi-centre, prospective, randomised controlled open label clinical trial, patients are divided into two arms: standard treatment arm and standard plus systemic corticosteroid arm. After twelve weeks; clinical, functional, and radiological improvement will being assessed as primary outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylprednisolone Tablet | Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks |
Timeline
- Start date
- 2021-05-24
- Primary completion
- 2021-12-31
- Completion
- 2022-01-31
- First posted
- 2021-08-03
- Last updated
- 2023-10-10
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT04988282. Inclusion in this directory is not an endorsement.